论文部分内容阅读
[目的]研究卡培他滨对于提高老年晚期结、直肠癌患者生存质量的作用。[方法]将548例一般状况较差并因多种因素无法接受常规静脉化疗、KPS评分为50~70分、经病理组织学或细胞学检查确诊的老年晚期结直肠癌患者分为研究组与对照组;研究组(438例)口服卡培他滨,对照组(110例)口服贞芪扶正胶囊;2组均在服药12周后行KPS评分以调查患者的生活质量的状况,以生活质量改善和稳定为治疗有效,以生活质量下降为治疗无效。[结果]研究组438例中,生存质量改善161例(占36.76%),生存质量稳定179例(占40.87%),生存质量下降98例(占22.37%);治疗有效340例(占77.63%),治疗无效98例(占22.37%)。对照组110例中,生存质量改善18例(占16.36%),生存质量稳定30例(占27.27%),生存质量下降62例(占56.36%);治疗有效48例(占43.64%),治疗无效62例(占56.36%)。研究组与对照组疗效比较差异有统计学意义(χ2=17.12,P<0.01)。研究组治疗中出现的不良反应比率较高,但无一例因不良反应而中止治疗。[结论]卡培他滨对于提高和稳定晚期结直肠癌患者生存质量有明显的作用。
[Objective] To study the effect of capecitabine on improving the quality of life in elderly patients with advanced node and rectal cancer. [Methods] 548 patients with poor general condition and unable to accept conventional venous chemotherapy due to various factors were divided into study group and control group with 50 ~ 70 points KPS score. The patients with advanced stage colorectal cancer diagnosed by histopathology or cytology were divided into two groups: The control group (438 cases) received capecitabine orally, while the control group (110 cases) took Zhenqi Fuzheng capsule orally. The KPS score was used to investigate the quality of life of the patients in both groups after 12 weeks. Stable for the treatment of effective quality of life decline for the treatment of ineffective. [Results] The quality of life improved in 161 cases (36.76%), the quality of life in 179 cases (40.87%), and the quality of life decreased in 98 cases (22.37%) in the study group of 438 cases; 340 cases (77.63% ), 98 cases of ineffective treatment (accounting for 22.37%). In the control group, quality of life was improved in 18 cases (16.36%), quality of life was stable in 30 cases (27.27%), quality of life was decreased in 62 cases (56.36%), treatment was effective in 48 cases (43.64%), Invalid 62 cases (56.36%). There was significant difference between the study group and the control group (χ2 = 17.12, P <0.01). There was a high rate of adverse reactions in the study group, but no case was stopped because of adverse reactions. [Conclusion] Capecitabine has a significant effect on improving and stabilizing the quality of life of patients with advanced colorectal cancer.